ORCID Profile
0000-0002-1450-730X
Current Organisation
Deakin University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 27-11-2013
Publisher: Elsevier BV
Date: 1991
Publisher: Springer Science and Business Media LLC
Date: 12-1980
DOI: 10.1007/BF02696542
Publisher: Elsevier BV
Date: 07-2011
Publisher: Wiley
Date: 15-08-2013
DOI: 10.1111/ROIE.12070
Publisher: Elsevier BV
Date: 2014
Publisher: Edward Elgar Publishing
Date: 26-08-2005
Publisher: Wiley
Date: 10-2003
Publisher: Springer Science and Business Media LLC
Date: 12-2006
Publisher: Elsevier BV
Date: 04-2012
Publisher: Informa UK Limited
Date: 06-2013
Publisher: Wiley
Date: 15-07-2010
Publisher: Wiley
Date: 29-01-2013
DOI: 10.1111/TWEC.12049
Publisher: Wiley
Date: 12-12-2015
DOI: 10.1111/TWEC.12247
Publisher: Elsevier BV
Date: 10-2003
Publisher: Elsevier BV
Date: 11-2014
Publisher: Elsevier BV
Date: 09-2005
Publisher: Elsevier BV
Date: 05-2011
Publisher: Elsevier BV
Date: 2013
Publisher: Elsevier BV
Date: 1992
Publisher: Elsevier BV
Date: 03-1976
Publisher: Elsevier BV
Date: 06-2004
Publisher: Walter de Gruyter GmbH
Date: 12-11-2012
Abstract: Following the passage of the Waxman-Hatch Act (1984), FDA approval for a generic drug requires the establishment of bio-equivalence between the generic drug and an FDA approved branded drug. However, a large body of evidence in the medical community suggests that bio-equivalence does not guarantee therapeutic equivalence in some instances the lack of therapeutic equivalence can lead to fatal consequences for patients switching to generic products. In this paper, we construct a simple model to analyze the implications of therapeutic non-equivalence between branded and generic drugs. We show, theoretically and empirically, that this distinction can provide a plausible explanation of the generic competition paradox.
Publisher: Wiley
Date: 08-2012
DOI: 10.1111/J.1540-5982.2012.01723.X
Abstract: Abstract For a small open economy with consumption‐based pollution emissions, the first‐best optimal policy prescription is free trade along with a Pigouvian tax on emissions. Therefore, a package of coordinated tax reform by replacing tariffs with emission taxes can lower pollution emissions and increase market access and hence improve residents’ welfare and government revenue, as long as the initial tariffs are relatively high. Numerical simulations confirm the results obtained.
No related grants have been discovered for Pasquale Sgro.